The 13 most recent market catalysts affecting $MEDP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Medicus Pharma shares are trading higher after the company provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company.
This headline represents a significant corporate catalyst for Medicus Pharma. The strategic update, particularly the focus on 'precision oncology,' is perceived as a high-growth, h…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on Medpace Holdings (MEDP) and raised the price target from $586 to $665. This action signals a positive outlook from a p…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 65
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600
BMO Capital analyst Sean Dodge has raised the price target for Medpace Holdings (MEDP) from $400 to $600, a substantial 50% increase, while keeping a 'Market Perform' rating. This …
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Maintains Outperform on Medpace Holdings, Raises Price Target to $692
RBC Capital analyst Ryan Halsted maintained an 'Outperform' rating on Medpace Holdings (MEDP) and substantially raised the price target from $484 to $692. This significant increase…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 95
Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
Medpace Holdings Inc. (MEDP) delivered a strong Q2 2026 performance, exceeding analyst expectations for both earnings per share and revenue. This positive surprise, coupled with a …
Jul 23, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Thursday's Pre-Market Session
This filing reports on the pre-market trading activity of 12 healthcare stocks, with six showing gains and six showing losses. The primary drivers for several of these movements ar…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 85
Medpace Holdings shares are trading higher after the company reported better-than-expected Q2 financial results and raised is FY26 guidance above estimates.
Medpace Holdings' better-than-expected Q2 results and raised FY26 guidance are a strong positive catalyst for the company, indicating robust operational performance and a healthy o…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
Charles River shares are trading higher amid sympathy with peer Medpace Holdings after the company reported Q2 financial results. Medpace's new business awards and net book-to-bill ratio suggests suggests industry growth.
The headline indicates a positive sentiment spillover from Medpace's strong earnings to Charles River Laboratories, suggesting a broader industry tailwind for Contract Research Org…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
Medpace Holdings Q2 New Business Awards $795.7M Up 28.2% YoY; Resulted In Net Book-To-Bill Ratio Of 1.13x
This headline is a strong positive catalyst for Medpace Holdings (MEDP). The 28.2% YoY increase in new business awards and a book-to-bill ratio of 1.13x indicate healthy demand for…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 85
Medpace Holdings shares are trading higher after the company reported better-than-expected Q2 financial results and raised is FY26 guidance above estimates.
This headline represents a significant positive corporate catalyst for Medpace Holdings. Better-than-expected Q2 results demonstrate strong current performance, while raising FY26 …
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 92
Medpace Hldgs Q2 EPS $4.25 Beats $3.97 Estimate, Sales $707.331M Beat $687.647M Estimate
Medpace Holdings announced its Q2 earnings, reporting an EPS of $4.25, which surpassed the consensus estimate of $3.97 by 7.05%. Sales also exceeded expectations, reaching $707.331…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $586
Mizuho's analyst Ann Hynes has maintained an 'Outperform' rating for Medpace Holdings and significantly raised the price target from $495 to $586. This action signals strong analys…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.